Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis

被引：0
|
作者：
Roy Fleischmann
机构：
[1] University of Texas Southwestern Medical School,Department of Medicine
[2] Metroplex Clinical Research Center,undefined
来源：
Clinical Rheumatology | 2021年 / 40卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4369 / 4372
页数：3
相关论文
共 50 条
  • [1] Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
    Fleischmann, Roy
    [J]. CLINICAL RHEUMATOLOGY, 2021, 40 (11) : 4369 - 4372
  • [2] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    [J]. RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [3] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Xerxes Pundole
    Natalia V. Zamora
    Harish Siddhanamatha
    Heather Lin
    Jean Tayar
    Leung Cheuk Hong
    Liang Li
    Maria E. Suarez-Almazor
    [J]. Clinical Rheumatology, 2020, 39 : 787 - 794
  • [4] The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs
    Pombo-Suarez, Manuel
    Gomez-Reino, Juan
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 148
  • [5] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Pundole, Xerxes
    Zamora, Natalia V.
    Siddhanamatha, Harish
    Lin, Heather
    Tayar, Jean
    Hong, Leung Cheuk
    Li, Liang
    Suarez-Almazor, Maria E.
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (03) : 787 - 794
  • [6] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    [J]. CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [7] Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
    Hanaoka, Hironari
    Kikuchi, Jun
    Hiramoto, Kazuoto
    Saito, Shuntaro
    Kondo, Yasushi
    Kaneko, Yuko
    [J]. CLINICAL KIDNEY JOURNAL, 2022, 15 (07) : 1373 - 1378
  • [8] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
  • [9] Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis
    Haibel, H.
    Specker, C.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S159 - S163
  • [10] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Clélia Monchablon
    Henri Gondé
    Sophie Pouplin
    Rémi Varin
    Olivier Vittecoq
    Thierry Lequerré
    [J]. Clinical Rheumatology, 2020, 39 : 207 - 216
12345